|
.jpg)
|
|
Proven. The AARC suggests "titrate to saturate" and the Eclipse 3 was designed with that theory in mind. With a comprehensive dosing selection, a broader patient population can be treated at rest, during sleep, at exercise and at altitude.
The Eclipse 3 will work for a majority of LTOT prescriptions.
- autoSAT Technology, a pulse delivery system, maintains a consistent pulse dose
volume for every breath as your patient's respiratory rate changes
- A fixed pulse dose volume up to 96mL (in increments of
16mL) in addition, three new pulse dose volumes of 128mL, 160mL and 192mL
- Three rise times (fast, medium and slow)
- In Continuous Flow, can be used with CPAP and bi-level devices
The Eclipse has been through rigorous testing and comparisons and has continually proven to be the winner.
|
"Recommending a POC that has the features the patient wants, yet does not oxygenate the patient, is not providing the clinical services the Respiratory Therapist should be providing and adds to the complications and costs that are currently burdening the health care system."
Robert McCoy, BS, RRT, FAARC
AARC Times September 2007
This information can be found in the American Association for Respiratory Care September 2007 Vol. 31, Issue 9.
|
|
|
Articles
How to Match POCs to Patient Needs
(HME Business
July 09)
The Clinical Impact of New LTOT Technology
(Respiratory Care Aug 09)
POC Performance
(AARC)
POC Capabilities
& Applications
Patients with Hemoglobin-opathies
(The Open Hematology Journal, 2010)
POC
Clinical Advantage Brochure
autoSAT Advantage Brochure
|
